Qiagen, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences deal

CeMM granted Qiagen an exclusive, worldwide license to the calreticulin (CALR) biomarker. Qiagen plans to use the biomarker to develop a CALR diagnostic to aid in prognostic profiling and disease man...